baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Novo Nordisk A/S/ DK0060534915 /

2/8/2023 5:00:00 PM	Chg. +7.70	Volume	Bid5:00:00 PM	Ask5:00:00 PM	Market Capitalization	Dividend Y.	P/E Ratio
973.20DKK	+0.80%	917,111 Turnover: 304.16 mill.	-Bid Size: -	-Ask Size: -	2761.87 bill.DKK	1.07%	46.70

GlobeNewswire 3/29/2022 Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business O...

GlobeNewswire 3/28/2022 Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business ...

GlobeNewswire 3/21/2022 Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childh...

GlobeNewswire 3/10/2022 Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzbur...

GlobeNewswire 3/3/2022 Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

GlobeNewswire 3/2/2022 Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential T...

GlobeNewswire 2/17/2022 Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidanc...

GlobeNewswire 2/17/2022 For second year, Degreed ranked high on enterprise capability and innovation in 2022 Fosway 9-Grid™ ...

GlobeNewswire 2/15/2022 NMD Pharma Raises €35 Million in a new Financing

GlobeNewswire 2/8/2022 Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

GlobeNewswire 2/7/2022 Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

GlobeNewswire 2/3/2022 Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discov...

GlobeNewswire 1/26/2022 Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rul...

GlobeNewswire 1/26/2022 Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

GlobeNewswire 1/20/2022 Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

GlobeNewswire 1/5/2022 Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

GlobeNewswire 1/4/2022 Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to includ...

GlobeNewswire 12/23/2021 Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

GlobeNewswire 12/8/2021 BrightInsight Named to the 2021 CB Insights Digital Health 150 List of Most Innovative Digital Healt...

GlobeNewswire 12/8/2021 Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders

GlobeNewswire 12/2/2021 Moore Kuehn Encourages ASPC, ROG, DRNA, and VG Investors to Contact Law Firm

GlobeNewswire 11/18/2021 GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients...

GlobeNewswire 11/18/2021 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.

GlobeNewswire 11/18/2021 DICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Con...

Novo Nordisk A/S/ DK0060534915 /

If you wish to receive reply to your feedback, please provide your email address.